
eTable 1. Changes in conventional DMARDs and oral corticosteroids during the study
eFigure. Kaplan-Meier curves for therapeutic maintenance in non-TNF and second anti-TNF groups

This supplementary material has been provided by the authors to give readers additional information about their work.
eTable 1. Changes in conventional DMARDs and oral corticosteroids during the study

<table>
<thead>
<tr>
<th>Methotrexate</th>
<th>Non-TNF biologic, n = 146</th>
<th>Second Anti-TNF drug, n = 146</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Week 24</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinuation</td>
<td>2/140 (1.4)</td>
<td>2/141 (1.4)</td>
</tr>
<tr>
<td>Dose decrease</td>
<td>17/140 (12.1)</td>
<td>4/141 (2.8)</td>
</tr>
<tr>
<td>No change</td>
<td>112/140 (80.0)</td>
<td>121/141 (85.8)</td>
</tr>
<tr>
<td>Dose increase</td>
<td>5/140 (3.6)</td>
<td>11/141 (7.8)</td>
</tr>
<tr>
<td>Initiation</td>
<td>4/140 (2.9)</td>
<td>3/141 (2.1)</td>
</tr>
<tr>
<td><strong>Week 52</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinuation</td>
<td>10/131 (7.6)</td>
<td>1/127 (0.8)</td>
</tr>
<tr>
<td>Dose decrease</td>
<td>14/131 (10.7)</td>
<td>5/127 (3.9)</td>
</tr>
<tr>
<td>No change</td>
<td>136/131 (97.2)</td>
<td>137/127 (97.2)</td>
</tr>
<tr>
<td>Dose increase</td>
<td>0/140 (0)</td>
<td>1/141 (0.7)</td>
</tr>
<tr>
<td>Initiation</td>
<td>0/140 (0)</td>
<td>1/141 (0.7)</td>
</tr>
<tr>
<td>Discontinuation</td>
<td>2/140 (1.4)</td>
<td>2/141 (1.4)</td>
</tr>
<tr>
<td><strong>Week 52</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinuation</td>
<td>2/131 (1.5)</td>
<td>3/127 (2.4)</td>
</tr>
<tr>
<td>Dose decrease</td>
<td>1/131 (0.8)</td>
<td>1/127 (0.8)</td>
</tr>
<tr>
<td>No change</td>
<td>125/131 (95.4)</td>
<td>120/127 (94.5)</td>
</tr>
<tr>
<td>Dose increase</td>
<td>0/131 (0)</td>
<td>1/127 (0.8)</td>
</tr>
<tr>
<td>Initiation</td>
<td>0/131 (0)</td>
<td>1/127 (0.8)</td>
</tr>
<tr>
<td>Discontinuation</td>
<td>3/131 (2.3)</td>
<td>1/127 (0.8)</td>
</tr>
<tr>
<td><strong>Conventional DMARD other than methotrexate</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Week 24</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinuation</td>
<td>2/140 (1.4)</td>
<td>0/141 (0)</td>
</tr>
<tr>
<td>Dose decrease</td>
<td>0/140 (0)</td>
<td>0/141 (0)</td>
</tr>
<tr>
<td>No change</td>
<td>136/140 (97.2)</td>
<td>137/141 (97.2)</td>
</tr>
<tr>
<td>Dose increase</td>
<td>0/140 (0)</td>
<td>1/141 (0.7)</td>
</tr>
<tr>
<td>Initiation</td>
<td>0/140 (0)</td>
<td>1/141 (0.7)</td>
</tr>
<tr>
<td>Discontinuation</td>
<td>2/140 (1.4)</td>
<td>2/141 (1.4)</td>
</tr>
<tr>
<td><strong>Week 52</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinuation</td>
<td>2/131 (1.5)</td>
<td>3/127 (2.4)</td>
</tr>
<tr>
<td>Dose decrease</td>
<td>1/131 (0.8)</td>
<td>1/127 (0.8)</td>
</tr>
<tr>
<td>No change</td>
<td>125/131 (95.4)</td>
<td>120/127 (94.5)</td>
</tr>
<tr>
<td>Dose increase</td>
<td>0/131 (0)</td>
<td>1/127 (0.8)</td>
</tr>
<tr>
<td>Initiation</td>
<td>0/131 (0)</td>
<td>1/127 (0.8)</td>
</tr>
<tr>
<td>Discontinuation</td>
<td>3/131 (2.3)</td>
<td>1/127 (0.8)</td>
</tr>
<tr>
<td><strong>Conventional DMARDs (methotrexate and others)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Week 24</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinuation</td>
<td>3/140 (2.1)</td>
<td>2/141 (1.4)</td>
</tr>
<tr>
<td>Dose decrease</td>
<td>17/140 (12.1)</td>
<td>4/141 (2.8)</td>
</tr>
<tr>
<td>No change</td>
<td>109/140 (77.9)</td>
<td>117/141 (83.0)</td>
</tr>
<tr>
<td>Dose increase</td>
<td>5/140 (3.6)</td>
<td>12/141 (8.5)</td>
</tr>
<tr>
<td>Initiation</td>
<td>1/140 (0.7)</td>
<td>1/141 (0.7)</td>
</tr>
<tr>
<td>Discontinuation</td>
<td>5/140 (3.6)</td>
<td>5/141 (3.5)</td>
</tr>
<tr>
<td><strong>Week 52</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinuation</td>
<td>10/131 (7.6)</td>
<td>4/127 (3.1)</td>
</tr>
<tr>
<td>Dose decrease</td>
<td>15/131 (11.5)</td>
<td>6/127 (4.7)</td>
</tr>
<tr>
<td>No change</td>
<td>88/131 (67.2)</td>
<td>101/127 (79.5)</td>
</tr>
<tr>
<td>Dose increase</td>
<td>10/131 (7.6)</td>
<td>12/127 (9.4)</td>
</tr>
<tr>
<td>Initiation</td>
<td>2/131 (1.5)</td>
<td>1/127 (0.8)</td>
</tr>
<tr>
<td>Discontinuation</td>
<td>6/131 (4.6)</td>
<td>3/127 (2.4)</td>
</tr>
</tbody>
</table>

© 2016 American Medical Association. All rights reserved.
<table>
<thead>
<tr>
<th>Oral corticosteroids (prednisone)</th>
<th>Non-TNF biologic, n = 146</th>
<th>Second Anti-TNF drug, n = 146</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Week 24</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinuation</td>
<td>6/142 (4.2)</td>
<td>4/141 (2.8)</td>
</tr>
<tr>
<td>Dose decrease</td>
<td>32/142 (22.5)</td>
<td>30/141 (21.3)</td>
</tr>
<tr>
<td>No change</td>
<td>80/142 (56.3)</td>
<td>85/141 (60.3)</td>
</tr>
<tr>
<td>Dose increase</td>
<td>14/142 (9.9)</td>
<td>11/141 (7.8)</td>
</tr>
<tr>
<td>Initiation</td>
<td>10/142 (7.0)</td>
<td>11/141 (7.8)</td>
</tr>
<tr>
<td><strong>Week 52</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinuation</td>
<td>13/127 (10.2)</td>
<td>9/131 (6.9)</td>
</tr>
<tr>
<td>Dose decrease</td>
<td>23/127 (18.1)</td>
<td>26/131 (19.8)</td>
</tr>
<tr>
<td>No change</td>
<td>63/127 (49.6)</td>
<td>70/131 (53.4)</td>
</tr>
<tr>
<td>Dose increase</td>
<td>14/127 (11.0)</td>
<td>12/131 (9.2)</td>
</tr>
<tr>
<td>Initiation</td>
<td>14/127 (11.0)</td>
<td>14/131 (10.7)</td>
</tr>
</tbody>
</table>
Therapeutic maintenance rate is defined as the proportion of patients who did not discontinue the biologic treatment initially assigned. Therapeutic maintenance was compared with a marginal Cox model. It was significantly higher in the non-TNF group at weeks 24 and 52 (79% vs 66%, HR 1.73, 95% CI [1.07; 2.82], p = 0.04 and 63% vs 47%, HR 1.69, 95% CI [1.18; 2.42], p = 0.01, respectively). Vertical ticks on the curves represent censored patients.